Clinical Report: Convergence of Physicochemical Properties in CDR3-VH Antibody Repertoires

Overview

This study investigates the development of recombinant antibody binders targeting phosphorothioate-modified antisense oligonucleotides (PS-ASOs) using a next-generation sequencing-guided phage display strategy. Key findings include a reduction in repertoire diversity and the emergence of shared CDR3 physicochemical signatures associated with PS-ASO recognition.

Background

Phosphorothioate-modified antisense oligonucleotides (PS-ASOs) are increasingly used in therapeutic applications due to their enhanced stability and efficacy. However, generating high-affinity antibodies that can effectively recognize these modified oligonucleotides presents significant challenges due to their unique physicochemical properties. Understanding the antibody repertoire's response to PS-ASOs is crucial for advancing therapeutic antibody development.

Data Highlights

Deep sequencing revealed a marked reduction in repertoire diversity from Round 1 to Round 2, indicating clonal dominance. A shared enriched set of 113 CDR3-VH clonotypes was identified with distinct physicochemical profiles.

Key Findings

• Reduction in repertoire diversity from Round 1 to Round 2 of selection.
• Identification of 113 CDR3-VH clonotypes with increased positive charge and reduced hydrophobicity.
• Functional assays showed that the scFv clone 12F2 preferentially binds to PS-ASOs.
• 12F2 produced detectable intracellular signals in ASO-treated cells.
• Physicochemical signatures suggest convergent binding solutions for PS-ASO recognition.

Clinical Implications

The findings provide a framework for identifying antibody candidates against challenging polyanionic targets like PS-ASOs. Understanding the physicochemical properties associated with successful binding may inform future antibody development strategies.

Conclusion

This study highlights the importance of physicochemical characteristics in the antibody repertoire's adaptation to recognize phosphorothioate-modified oligonucleotides, paving the way for improved therapeutic antibody design.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges
2. Blood Cancer Journal, 2024 -- Identification of T-cell Neoplasms via Flow Cytometry Using Dual Staining for T-cell Constant β Chains TRBC1 and TRBC2
3. The Journal of Infectious Diseases, 2024 -- Conservation of the Binding Epitope for AZD5148, a Broadly Neutralizing Monoclonal Antibody Against Toxin B, Across Diverse Global Clostridioides difficile Strains
4. Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics | FDA
5. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial - PubMed
6. Acta Neuropathologica — Nuclear RNA foci formation and repeat-associated non-ATG translation of antisense transcripts linked to the expanded C9ORF72 hexanucleotide repeat in c9FTD/ALS
7. Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics | FDA
8. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial - PubMed
9. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome | New England Journal of Medicine